Wang Cenrong, Tang Xin, Jiang Chenghan, Zhang Yu, Han Bo, Sun Yi, Guo Jianfeng, Peng Hanyu, Wang Zihan, Wang Yipeng, Zhang Jialu, Zhang Yong, Jiang Chunlai
National Engineering Laboratory for AIDS Vaccine, School of Life Sciences, Jilin University, Changchun, China.
R&D Department, Changchun BCHT Biotechnology Co., Changchun, China.
Front Immunol. 2025 Feb 17;16:1530736. doi: 10.3389/fimmu.2025.1530736. eCollection 2025.
Needle-free injection system (NFIS) is easy to operate and can decrease needle phobia. Besides, NFIS can increase the interaction of antigens in a more dispersed manner with immune cell at local injection site, which may improve the immune responses of mRNA vaccines. Although SARS-CoV-2 mRNA vaccines have great success, universal vaccines are urgently needed. Delivering universal mRNA vaccines by NFIS is preferred to combat COVID-19.
RBD3-Fc mRNA expressing BA.4, Delta, and prototype RBD, and human IgG Fc with YTE mutation was designed and synthesized. The safety and immune responses of universal RBD3-Fc naked mRNA and mRNA-LNP vaccines delivered intradermally using NFIS (named GV-01) and intramuscularly via needles were evaluated and compared in rats.
The prime-boost regimen administered by two routes resulted in potent immune responses and intradermal delivery displays comparable or better performance in terms of binding antibodies, neutralizing antibodies and T cell responses. Naked mRNA vaccines were functional, but less effective than mRNA-LNP vaccines.
The above results suggest that RBD3-Fc vaccines are safe and immunogenic and NFIS can be used as an alternative to needles/syringes for the inoculation of mRNA-LNP vaccines to elicit robust systematic immune responses.
无针注射系统(NFIS)操作简便,可减轻针头恐惧症。此外,NFIS能够使抗原在局部注射部位以更分散的方式与免疫细胞相互作用,这可能会增强mRNA疫苗的免疫反应。尽管严重急性呼吸综合征冠状病毒2(SARS-CoV-2)mRNA疫苗取得了巨大成功,但通用疫苗仍亟待研发。采用NFIS递送通用mRNA疫苗是对抗2019冠状病毒病(COVID-19)的首选方法。
设计并合成了表达BA.4、Delta和原型受体结合域(RBD)的RBD3-Fc mRNA,以及带有YTE突变的人免疫球蛋白G(IgG)Fc。在大鼠中评估并比较了使用NFIS皮内注射(命名为GV-01)和通过针头肌肉注射通用RBD3-Fc裸mRNA疫苗和mRNA-脂质纳米颗粒(LNP)疫苗的安全性和免疫反应。
两种途径给予的初免-加强方案均产生了有效的免疫反应,且就结合抗体、中和抗体和T细胞反应而言,皮内给药表现出相当或更好的性能。裸mRNA疫苗具有功能性,但效果不如mRNA-LNP疫苗。
上述结果表明,RBD3-Fc疫苗安全且具有免疫原性,NFIS可作为接种mRNA-LNP疫苗的针头/注射器替代品,以引发强大的全身免疫反应。